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Abstract
Background External reference pricing (ERP) is widely used to regulate drug prices. Although the literature has largely 
focused on the impact of ERP on a number of policy endpoints and its impact from a geographical perspective, a compara-
tive study drawing on evidence from different settings does not exist to date.
Methods A systematic literature review was conducted on pre-defined endpoints on the impact of ERP across countries, 
such as price stability, price convergence and launch delays. Expert consultation was undertaken to analyse whether or not 
the international implications of ERP are considered during its design.
Results 46 studies were included in the analysis. Across countries, ERP may cause launch delays, price instability and lead 
to price convergence. However, these effects cannot be solely attributed to ERP, as there may be other factors at play, such 
as the size and the GDP of a country and other regulations in place, which can trigger these effects or reduce their effect. 
Nevertheless, the nature of ERP facilitates these unintended consequences and directly links them to it. Despite these cross-
country implications being well known to decision-makers, they are not necessarily considered during the design of ERP.
Conclusions As the effects of ERP as a stand alone policy are very difficult to isolate in the presence of other regulatory meas-
ures implemented within countries and the presence of other extrinsic factors across countries, our findings are inconclusive. 
Still, there is an unquestionable unmet need related to the design of ERP systems to attain a positive impact internationally.
Keywords External reference pricing · Pharmaceutical pricing · Pharmaceutical policy · Systematic review · Regulation of 
pharmaceuticals · Expert consultation
JEL Classification I · I1 · I10 · I11 · I18
Introduction
External price referencing (ERP) is defined as “the practice 
of using the price(s) of a medicine in one or more countries 
in order to derive a benchmark or reference price for the 
purpose of setting or negotiating the price of the product 
in a given country” [1]. Over time, ERP has been consid-
ered to be a powerful tool that influences prices at national 
and international level, due to the interlinking of prices 
and path dependency, in that the features of an ERP system 
influence the overall outcome within and across countries 
[2–5]. Despite the extensive implementation of ERP over 
a long time period, many countries have started to rely on 
other methods to inform prices, such as cost-effectiveness 
analysis, price negotiations and Managed Entry Agreements 
(MEAs) [6]. This is because several shortcomings have been 
identified with the use of ERP in different settings, includ-
ing, among others, the fact that prices taken as reference 
do not reflect transaction prices in the reference countries 
and its perception as a price reduction and cost contain-
ment method, rather than an efficient resource allocation 
tool [4, 5, 7–9]. A further shortcoming is that ERP may 
lead to cross-country spillover effects such as launch delays 
with concomitant implications for access [7, 8, 10–13]. Price 
convergence, towards the basket’s average, median or lowest 
price (depending on country stipulations) is observed as a 
result of ERP, while price instability can also be triggered as 
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price fluctuations in one country may generate greater price 
fluctuations in another [4, 5, 8, 9, 14].
Elsewhere, it has been shown that there is a lack of empir-
ical evidence with clear methodological design and scarce 
evidence on the reasons why ERP impact varies within and 
across countries [15]. In this paper, we study the interna-
tional implications of reference pricing and the extent to 
which these affect national policy objectives.
Based on the above, the objective of this paper is twofold: 
first, to study the implications of ERP systems at interna-
tional level, particularly considering their likely spillover 
effects and access implications; and second to critically 
assess the quality and strength of evidence found in the lit-
erature against a set of pre-defined endpoints. To our knowl-
edge, there is no other review up to this point examining the 
international implications of ERP and investigating whether 
policy-makers are considering these while designing an ERP 
system; and it is the first review, which appraises the qual-
ity of available evidence in order to establish whether the 
results of the potential impact of ERP across countries are 
robust or not.
Conceptual background
The justification for price intervention in pharmaceutical 
markets characterised by the entry of new and in-patent 
pharmaceutical products is provided by the predictions of 
monopoly pricing or monopolistic behaviour on the part of 
the innovator. As decision-makers face monopoly prices 
leading to less than optimal market coverage, the response 
would be to either impose a regulated price ceiling on entry 
prices of new products or to arrive at a suitable price based 
on an objective value assessment mechanism. Faced with the 
inability to identify a suitable or ‘fair’ entry price below the 
monopoly price and the lack of capability to assess the value 
of new pharmaceutical products based on objective criteria, 
a number of decision-makers rely on prices available in other 
settings. ERP is a pricing tool that has been used widely 
across countries, already since the late 1990s (e.g. in Greece, 
Italy, Portugal and Slovenia) [16]. When implementing a 
regulated price, it is hoped that this will contain the rate of 
growth of pharmaceutical costs, whilst at the same time help 
improve resource allocation decisions. As pharmaceutical 
suppliers typically launch products in settings where they 
can achieve the highest possible list prices, notably where 
explicit price regulation is not applied, the pool of reference 
countries to serve as a foundation for ‘reference prices’ to 
rely on is small. The launch of the same product in multi-
ple settings, enables countries implementing ERP to update 
their price levels regularly and pursue price reductions at 
regular intervals based on the design characteristics of their 
ERP systems. Specifically, four key design elements lead 
to gradual price reduction and, consequently, cost minimi-
sation: first, selection of reference countries for inclusion 
in country baskets, giving greater emphasis on low-price 
countries; second, selection of the reference price from the 
basket, emphasising the lowest in the basket or the aver-
age among the lowest quartile, quintile or decile of basket 
countries; third, the frequency of price revisions, in order to 
accelerate the process of price diminution; and, fourth, the 
use of ‘favourable’ exchange rates in order to arrive at even 
lower prices. Unavoidably, these design characteristics of 
ERP can deliver significant price reductions over time, and 
as significant cross-country referencing exists, a process of 
gradual price convergence towards the lowest is triggered.
From a game-theoretic perspective, manufacturers can pre-
dict the behaviour of countries that apply ERP, particularly 
as ERP design characteristics are embedded into legislation 
and, therefore, are publicly available. Consequently, manu-
facturers calibrate the sequence of market entry in such a way 
as to maximise gains from individual markets and minimise 
the effect of stepwise price reductions. The prospect of sig-
nificant price diminution triggers a protective behaviour from 
manufacturers to delay the launch of products that are likely 
to be affected, or altogether not launching new products if 
such price diminution is likely to jeopardise prices in other 
markets. Manufacturers may adopt this strategy in order to 
minimise, or altogether eliminate, the spillover effects of cost 
minimisation from one setting into others. These spillover 
effects create deterministic pathways leading to a reduction in 
prices in all the countries using ERP, ultimately, triggering a 
race towards the lowest. As such, therefore, ERP has signifi-
cant cross-border implications, which may transcend regional 
geographies, as cross-country referencing may not be limited 
to countries in the same geographical region, but can include 
countries from across geographies.
Taking the above into consideration and building on 
work undertaken previously on the subject [17], we created 
a framework in order to examine the international implica-
tions of ERP and the extent to which these implications are 
observed in the literature. In sum, the international implica-
tions include (a) the overall impact of spillover effects; (b) 
the potential impact of ERP on price stability; (c) the extent 
of price convergence across countries and (d) the extent of 
launch sequencing and launch delays. Table 1 summarises 
these endpoints and the issues generated by them.
Methods
The evidence informing this paper comes from a systematic 
literature review, which was carried out in accordance with 
the CRD guidelines for systematic reviews [18]. This was 
complemented by targeted primary data collection to better 
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understand whether policy-makers take into consideration 
the international implications of ERP during its design.
Systematic literature review
Data sources
Evidence was collected according to a set of pre-defined 
endpoints based on the framework outlined in Table 1. There 
were no country-specific restrictions imposed on our search 
to ensure that evidence from a wide geographical range was 
collected. The study period for inclusion of relevant pub-
lished studies was from January 2000 to December 2016. 
The start-date coincides with the period many countries 
started to implement ERP [2, 11, 13, 16].
To ensure the identification of all relevant information 
both peer-reviewed and grey literature were examined and 
included. Seven databases were searched [the Web of Sci-
ence (WoS), CINAHL, EconLit, Medline, ProQuest, the 
Cochrane Library and Scopus] using the following key-
words: “Pharmaceutical Price Regulation” OR “Pharma-
ceutical Regulation” OR “Cost Containment” OR “Phar-
maceutical Pricing” OR “External Reference Pricing” OR 
“External Price Referencing” OR “International Price Com-
parisons” OR “International Reference Pricing” OR “Inter-
national Price Referencing” AND drug OR drugs OR medi-
cine OR medicines OR pharmaceutical OR pharmaceuticals. 
In addition to the systematic review and grey literature, a 
targeted search of the WHO, the WHO Collaborating Cen-
tre for Pharmaceutical Pricing and Reimbursement Policies-
Gesundheit Österreich (WHOCC-GOEG), the OECD online 
databases and the European Commission was carried out to 
ensure that no relevant reports were omitted. The keywords 
used to search these databases were “External Reference 
Pricing” OR “External Price Referencing” OR “Interna-
tional Reference Pricing” OR “International Price Referenc-
ing”. Relevant information was recorded and combined with 
the results of the systematic literature review.
Study selection and data extraction
The following stages were followed to select studies and 
extract data in adherence with the CRD guidelines: first, 
search results were filtered based on title and abstract rel-
evance. Evidence from grey literature was also included 
in the systematic literature review in order to ensure that 
all relevant studies were considered. Studies with relevant 
titles were downloaded for further examination. The main 
body of these studies was then assessed for relevance against 
the inclusion criterion, notably, “mention of external price 
referencing and its impact across countries” at least in 
one of the selected endpoints in order to give a final set 
of potentially relevant studies. The number of documents 
presenting evidence on each endpoint was noted. Where one 
study presented evidence on more than one endpoint, this 
was recorded separately each time. An excel spreadsheet 
was used to extract the relevant information on each end-
point from the final set of studies included in this study. 
The spreadsheet comprised study titles in rows versus the 
endpoints in columns, with important information from the 
extracted texts. Where the search yielded studies, which 
were the product of a systematic literature review, they were 
Table 1  Endpoints on the impact of ERP at international level Source: The authors
Endpoints Definition Issues
Spillover effects Assesses the effects expected to a certain extent by ERP, 
which can prove problematic for the achievement of 
national government policy objectives, e.g. spillover 
effects. Spillover effects are a deterministic pathway 
through which the basket of countries is selected based on 
lowest price criteria
Impact of spillover effects
Price stability Assesses the potential of ERP to help stabilise pharmaceuti-
cal prices so that random fluctuations caused by, among 
others, unrelated events such as currency fluctuations, are 
prevented
ERP has the ability to promote price stability across countries
Price stability depends on ERP design
Price stability depends on market characteristics
Price convergence Examines whether ERP leads to price convergence (and 
whether this is upward or downward) or price divergence
ERP leads to price convergence across countries
Type of price convergence (upward or downward) depends on 
ERP design
Price convergence depends on exogenous factors other than 
ERP
Launch delays Examines whether there are delays in the launch of new 
pharmaceuticals in third countries, exclusively due to ERP 
rather than other regulatory measures, e.g. HTA, claw-
backs, rebates, among others
Impact of ERP on pharmaceutical product launch
Impact of ERP on launch sequencing
Launch delays and launch sequencing may depend on factors 
other than ERP
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only included in our analysis if the endpoints considered 
were different from those set out in this study, in order to 
gather as much information as possible whilst at the same 
time avoiding any possible bias. The same criteria in terms 
of timeline, language, keywords, title and abstract relevance 
were applied for both peer-reviewed and grey literature.
Evidence assessment
We did not expect to identify experimental designs in the 
studies included in this review. We, therefore, departed from 
the paradigm of assessing risk of bias in experimental stud-
ies used for healthcare interventions, such as randomised 
controlled trials, and assessed the quality of designs used 
in policy studies, including policy interventions. Strong 
designs such as quasi-experimental designs (based on the 
hierarchy ranging from time-series with or without com-
parator group, pre–post with or without comparator group 
and post-only designs), are often used to assess the impact 
of policy interventions [19] and provide different degrees 
of robustness. We categorised the studies identified in this 
review into empirical and non-empirical. The former com-
prised any randomised and non-randomised controlled 
trials, studies using quasi-experimental designs and other 
quantitative analyses. The latter, included theoretical mod-
els, descriptive studies as well as other literature reviews. 
Where descriptive studies provided quantitative evidence 
for a particular study endpoint(s), the initial piece of evi-
dence was identified to assess its study design and its quality. 
We recorded both the study design and study timeline in all 
identified studies: the type of study design would enable us 
to make inferences about the robustness of the evidence and 
the extent to which it could provide meaningful policy rec-
ommendations; and study timelines would enable us to make 
inferences about short- or long-term implications, consider-
ing the likely effects of ERP on a policy variable or endpoint 
of 3 years or less to be “short-term” in nature.
Primary data collection
Primary evidence was generated using a brief survey as a 
supplement to the evidence resulting from the systematic 
literature review. The aim was to understand whether key 
stakeholders in national competent authorities consider 
the international implications of ERP during its design. 
Respondents from national competent authorities, insurance 
organisations, academic institutions and the pharmaceuti-
cal industry were asked to provide evidence, and their per-
sonal opinion, on the international implications of ERP as 
summarised in Table 1. The input received would represent 
the personal perspective of the respondents and not that of 
their institutions. The survey was administered via email 
between January and July 2017 to key stakeholders from 
21 countries that implemented some form of ERP during 
the study period (Belgium, Brazil, Bulgaria, Egypt, Estonia, 
France, Germany, Greece, Hungary, Italy, Jordan, Latvia, 
Poland, Portugal, Qatar, Romania, Russia, Slovakia, Slo-
venia, South Africa and Spain). The country selection was 
made taking into consideration countries across the world, 
which implement ERP either as a primary or supportive tool 
in price setting.
Data synthesis
Results of the review were presented in a narrative way 
under each endpoint to summarise our findings, based on 
the CRD guidelines complemented by the evidence from 
primary data collection where applicable. We used the 
framework on Table 1 and the issues that each endpoint 
raised, to summarise the evidence from the peer-review 
and grey literature. Separately, we endeavoured to discuss 
the quality of evidence in support of the endpoints in order 
to gauge whether the documented effects might have been 
over- or under-estimated. For this purpose, a simple-vote 
counting approach was used to determine the accumulated 
impact of ERP on each endpoint and issues identified for 
each endpoint.
Based on the above, a template synthesising the results 
of this study was created and was populated with the results 
of the review summarised in four dimensions: first, the 
direction of impact (i.e. positive or negative) that ERP was 
found to have on the identified endpoints; second, the qual-
ity of the empirical evidence considered under individual 
endpoints (classified as high, moderate, low and very low); 
third, the overall extent of evidence in terms of number of 
studies identified regardless of their quality (high, moder-
ate, low, very low) and; fourth, whether the studied end-
points and issues have been studied over the short- or long-
term. Table 3 contains the synthesis based on these four 
dimensions.
Results
Systematic literature review
Figure 1 shows the PRISMA flow diagram of the review 
process and the respective number of articles at each stage. 
The database search yielded 6875 peer-reviewed and grey 
literature studies. The results of the systematic literature 
search were then combined with the results from the targeted 
search. Following removal of duplicates, using the EndNote 
software, 3977 studies were screened based on relevant titles 
and abstracts. Of these, 3489 studies were peer-reviewed 
and 488 were grey literature. 507 studies were identified as 
potentially useful and read in full to assess for eligibility. 
1151International impact of external reference pricing: should national policy-makers care? 
1 3
Studies were excluded if they were not relevant to ERP, 
focused on internal reference pricing, if full texts were not 
available and when they focused on the implications of ERP 
at a national level, which falls outside the scope of this study. 
The content of 46 studies was finally used to inform the 
findings. Four studies included in this systematic literature 
review were empirical studies (8.5% of all included studies). 
Although the majority were a combination of descriptive 
studies, theoretical models or literature reviews, it has been 
observed that when examining the impact of ERP against 
the included endpoints, these studies used data collected 
by studies using a post-only design in order to capture the 
impact of ERP quantitatively. In such cases, the original data 
source was studied and recorded.
One systematic literature review [20] was extracted via 
our systematic literature search, which provided an overview 
of the process and potential issues of ERP systems in Euro-
pean countries including Iceland, Norway, and Switzerland. 
In this study, the authors examined the use of ERP and its 
impact on the prices of pharmaceuticals as well as the possi-
ble cross-country coordination issues in European countries. 
However, the scope and endpoints studied in this systematic 
literature review differ from the current analysis. The present 
search strategy was not limited to countries in the European 
region and had no country-specific limits. Therefore, we 
were able to include this study in our analysis. In addition, 
other non-systematic reviews [5, 21], which differ in scope, 
were included in this systematic literature review. A discus-
sion of all available evidence by endpoint, along with issues 
identified for each endpoint, can be found in the sections that 
follow, while a summary is presented in Table 2.
Impact of spillover effects
The term ‘spillover’ effects is typically used to describe 
the impact of ERP across borders. To achieve lower prices, 
ERP systems are designed based on a pre-defined basket, 
which usually contains low-price countries. Even though 
high-price countries might be included in the basket, most 
countries use the lowest price in the basket to calculate refer-
ence prices, which again will result in a reduced price in the 
country implementing ERP. In other words, spillover effects, 
which are embedded in ERP systems, follow deterministic 
pathways through which, prices are reduced across coun-
tries implementing ERP and are highly dependent on the 
construction of the basket and the way the reference price is 
calculated. Therefore, these effects are unavoidably experi-
enced due to the nature of ERP itself.
We found that spillover effects indirectly cause price cuts 
in one country to be transferred to a third country [12]. A 
simulation model found that a 10% price cut in Romania 
(referenced by Greece and Bulgaria), would have caused 
Fig. 1  PRISMA flow diagram 
outlining search results from 
the systematic literature review 
on international implications 
of external reference pricing. 
Source: The authors
Records excluded due to irrelevance 
of title or abstract (n= 3,470)
Full text articles excluded (n=461)
Records identified through database 
searching (n= 6,875)
Additional records identified through other 
sources (n= 143)
Records after duplicates removed (n= 3,977)
Records screened (n= 3,977)
Full text articles assessed for eligibility 
against inclusion criteria (n= 507)
Final studies included (n= 46)
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Table 2  Summary of the evidence on the international impact of ERP Source: The authors based on literature review findings and primary data collection
Endpoints Issues Overall evidence Countries with evidence Quantifiable impact Short-term vs. long-term effect
Impact of spillover effects Spillover effects ERP implementation is associated 
with spillover effects that can be 
observed across countries. These 
effects indirectly cause the implica-
tions of a price cut in one country 
to be transferred to a third country, 
which references the countries 
where the price cuts took place [4, 
8, 12, 20]
All EU and OECD countries In a simulation exercise, a 10% price 
cut in Romania caused considerable 
indirect effects even in countries 
not referencing Romania. The 
prices in the Czech Republic 
and Portugal were 3% and 2% 
lower, respectively, only because 
of the Romanian price cut. This 
is because the Czech Republic 
and Portugal’s reference baskets 
contain countries (Greece and/or 
Bulgaria), which reference Roma-
nia. Similarly, spillover effects can 
be observed in countries, which 
do not reference countries with an 
established ERP system only. In 
the same simulation, prices in the 
Netherlands dropped by 0.64% due 
to the 10% price cut in  Romaniab
Whether ERP causes spillover effects 
in the short- or the longer-term has 
not been studied extensively in the 
literature
Price stability ERP has the ability to promote price 
stability across countries
Overall, the impact of ERP on prices 
in other countries is not very well 
understood. However, the ability 
of ERP to stabilise pharmaceutical 
prices depends largely on other 
market characteristics as well as on 
the ERP design [4, 7, 8, 20, 23–29]
EU countries and Switzerland • A 10% price drop in Greece is esti-
mated to be associated with losses 
for the industry of €299 million in 
Greece, €799 million in other Euro-
pean markets, and €2,154 million 
 worldwidea
• A 10% price reduction in Swiss 
prices would reduce industry reve-
nue by €430 million in Switzerland 
and €495.2 million  worldwidea
• A €1 reduction in German 
prices would translate into a price 
reduction of €0.09 in Austria, 
which uses Germany as a reference
• Finally, an additional, indirect, 
reduction of €0.15–€0.19 would 
also be seen as a result as Austria 
benchmarks several countries that 
use Germany in their reference 
 basketa
The frequency of price revisions 
and exchange rate volatility play a 
significant role in price stability and 
might lead to decreases in the prices 
of pharmaceuticals in the mid- to 
long-term. In Italy, the effects of 
price decreases across Europe were 
found to cause price erosion in the 
entire pharmaceutical market over 
time
Price stability depends on ERP 
design
The extent to which price stability 
is maintained across countries 
depends largely on the design of 
ERP. The intensity of price revi-
sions, the composition of the coun-
tries in the basket and the number 
of reference countries can either 
promote or hinder price stability 
across borders [7, 9, 50]
All EU countries, USA, New Zealand, 
Japan, Australia, Canada, Mexico, 
South Africa
A systematic price revision occurring 
annually would almost double the 
price decrease compared to a situ-
ation where a price revision occurs 
every 3 yearsb
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Table 2  (continued)
Endpoints Issues Overall evidence Countries with evidence Quantifiable impact Short-term vs. long-term effect
Price stability depends on market 
characteristics
Price stability depends on the coun-
tries used as reference, the launch 
sequencing strategies adopted by 
manufacturers, whether the refer-
ence countries have strict price 
regulations, the type of pharmaceu-
ticals which are subject to ERP, and 
on other measures such as confi-
dential rebates/clawbacks that are 
implemented in each reference 
country [4, 8, 20, 24–29]
All EU countries and Switzerland • A 10% price drop in Greece is esti-
mated to be associated with losses 
for the industry of €299 million in 
Greece, €799 million in other Euro-
pean markets, and €2,154 million 
 worldwidea
• A 10% price reduction in Swiss 
prices would reduce industry reve-
nue by €430 million in Switzerland 
and €495.2 million  worldwidea
• A €1 reduction in German 
prices would translate into a price 
reduction of €0.09 in Austria, 
which uses Germany as a reference
• Finally, an additional, indirect, 
reduction of €0.15–€0.19 would 
also be seen as a result as Austria 
benchmarks several countries that 
use Germany in their reference 
 basketa
Price convergence ERP leads to price convergence 
across countries
When implemented across European 
countries, other OECD countries 
and the Middle East, ERP leads to 
some price convergence [2–5, 8, 9, 
14, 20, 22, 30–35]
All EU and OECD countries, Middle 
East countries, Canada
• In the Middle East, the average 
price corridor is narrower for phar-
maceuticals (− 39.8% + 35.9%) 
than for outpatient and hospital ser-
vices (− 81.7% + 96.3%) (2014)a
• Price divergence between Germany, 
which has up to 27% higher  phar-
maceutical prices than the Euro-
pean average, and Greece, which 
has up to 32% lower  pharmaceuti-
cal prices than the  averagea
• In a simulation exercise, applying 
ERP as the sole pricing rule led 
to an average drug price decrease 
of about 15% in 10 years. Price 
differentials between countries 
remained substantial—around 
30%—over this period, suggesting 
a limited impact of ERP on price 
 convergenceb
There is some price convergence across 
European countries in the long run 
due to ERP
Type of price convergence (upward 
or downward) depends on ERP 
design
The extent of price convergence 
towards European average prices 
depends on the size of national bas-
kets, the price considered in the 
ERP formula and the frequency of 
price revisions [3–5, 9, 31–35]
All EU countries • As the basket of countries increases 
in size, ERP can lead to price con-
vergence towards the  meana,b
• ERP can lead to a downward price 
convergence in Europe, when the 
lowest price in the basket is used to 
calculate the reference  priceb
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Table 2  (continued)
Endpoints Issues Overall evidence Countries with evidence Quantifiable impact Short-term vs. long-term effect
Price convergence depends on exog-
enous factors other than ERP
The extent of price convergence 
towards international prices 
also depends on exogenous factors 
such as possible currency fluctua-
tions and parallel trade (the latter 
being relevant in the European 
context) [9]
All EU countries Applying ERP as the sole pricing 
rule in a simulation exercise led 
to an average drug price decrease 
of about 15% in 10 years. Price 
differentials between countries 
remained substantial—around 
30%—over this period, suggesting 
a limited impact of ERP in price 
 convergenceb
Launch delays Impact of ERP on pharmaceuti-
cal  product launch
ERP has an unambiguous impact on 
the timing of pharmaceutical launch 
across countries [3–5, 7–13, 20, 21, 
29, 30, 36–52]
All EU countries, Switzerland, USA, 
Australia, Canada, Mexico, South 
Africa, Japan, Turkey, Taiwan, New 
Zealand
• The average launch delay ranged 
from 8.1 months in Germany to 
17.4 months in Belgium (in mid-
1990s)a
• Portugal had to wait an average 
of 46 months for new oncology 
drugs. By contrast, Switzerland and 
the Netherlands had to wait just for 
5 months (2001–2013)b
• For diabetes pharmaceuticals, 
Croatia had the longest delay at 
37 months, while Switzerland 
had the shortest delay of just 1 
month  and five other European 
countries waited only about 2 
months (2001–2013)b
50% of (n = 8) the identified studies 
present long-term evidence on 
whether ERP affects pharmaceutical 
launch over a period of time
Impact of ERP on launch sequencing Manufacturers are adopting launch 
sequencing strategies to delay 
the launch of new pharmaceuticals 
in countries with lower prices, 
smaller market size and strict regu-
lations on price setting [3–5, 7–13, 
20, 36–49]
All EU countries, Turkey, Taiwan • In Taiwan and Turkey manufactur-
ers are reluctant to launch new 
 medicinesb
• Lower income Eastern and South-
ern European countries tend to 
face longer launch delays than their 
Western and Northern European 
 counterpartsa,b
• During the mid-to-late 1990s, 
Greece, Belgium and France, had 
the longest average delay between 
drug approval and marketing, 
whereas, Germany, the USA and 
the UK, had the shortest average 
 delaya
• Manufacturers listed countries with 
the least interventionist pricing sys-
tem (UK, Germany and Sweden) 
as preferred for product launch, in 
contrast to countries with smaller 
markets, such as Cyprus or Malta, 
or countries with lower disposable 
income, such as Poland, Bulgaria, 
Lithuania, Latvia, Estonia, Hungary 
and Romania, which are also 
associated with price regulation 
through  ERPa
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indirect spillover effects even in countries not using Roma-
nia in their basket. For instance, prices in the Czech Repub-
lic and Portugal would have been 3 and 2 per cent lower, 
respectively, because of the Romanian price cut. This is 
because the Czech Republic and Portugal’s reference baskets 
contain countries (Greece and/or Bulgaria), which reference 
Romania [12]. Similarly, spillover effects can be observed 
in countries with mixed baskets (notably containing both 
countries using and not using ERP). In the same simulation, 
prices in the Netherlands dropped by 0.64% due to the 10% 
price cut in Romania. Of the countries included in the Dutch 
reference basket, only Belgium was using ERP (which, in 
turn, references Romania) and the price reduction in the 
Netherlands came from the effect of Romanian price reduc-
tion into Belgian prices [12].
Low price levels in one country can indirectly affect 
manufacturer pricing strategies elsewhere and potentially 
lead to increases in parallel trade [8, 20, 22]. Therefore, the 
spillover effects of low prices observed due to ERP systems 
across Europe can be a major concern for manufacturers, 
often leading to launch delays, promoting launch sequenc-
ing strategies and potentially result in limited access [8, 20]. 
While the vast majority of the negative spillover effects dis-
cussed above relate to the phase when a product has been 
launched in many settings and, therefore, ample opportu-
nities for cross-referencing and price diminution exist, in 
the initial phases, spillover effects can be positive: when 
only few countries experience product launch, typically, not 
affected by price controls, their prices are taken as reference 
in settings where price controls exist [8].
Price stability
Price stability centres on the potential of ERP to help stabi-
lise pharmaceutical prices across countries, such that ran-
dom fluctuations, for example due to the effect of different 
currencies, are prevented. The evidence from this endpoint 
addresses four specific issues: (1) whether ERP has the abil-
ity to promote price stability across countries; (2) whether 
price stability is realised in the short-, medium- and long-
term; and examines possible factors that might affect the 
level of price stability, including (3) the ERP methodology 
or (4) other externalities.
In the literature ERP’s ability to produce stable prices 
across countries and over time is not very well understood. 
This can be partly attributable to the substantial price dif-
ferences observed among European countries implementing 
ERP [4].
The variation seen in ERP design across countries may 
indirectly affect price stability. Countries not only vary 
in the composition and size of their reference basket, but 
they also tend to employ different calculation methods to 
determine the reference price [23]. The apparent trend is Ta
b
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for lower-price countries to be used as a reference, with the 
reference price deriving as a function of the lowest third 
or quartile in the selected basket. In addition, the use and 
frequency of price revisions, exchange rate volatility and 
the tendency of country baskets to revert towards the lowest 
price, can significantly sabotage price stability. The afore-
mentioned features of ERP may exert a downward pressure 
on pharmaceutical prices in the mid- to long-term in a par-
ticular country and lead to cross-border knock-on effects [7]. 
In particular, the frequency of price revision is an important 
driver of price changes over time when applying ERP. It has 
been estimated that when systematic price revisions take 
place every year, the price decrease seen is almost double 
than the one seen when price revisions take place only every 
three years [9]. Thus, revising the intensity of price revisions 
in all countries will affect those with long periodicity, as 
increasing the revision frequency will contribute to decreas-
ing overall pharmaceutical prices. This price decrease will 
further impact the prices in countries with high frequency 
of revision because of the referencing system, leading to 
unstable prices across countries [9]. Other factors related 
to ERP design, such as differing approaches used to tackle 
exchange rate fluctuations within the basket, the size of the 
basket, the ERP formula used and the different pricing poli-
cies implemented by the reference countries in the basket 
may also have an effect on price stability, however evidence 
on this in the literature is lacking.
With regards to external factors that could potentially 
affect price stability due to frequent price changes, ERP 
(a) places greater pressure on countries that are referenced 
by others to keep prices high, (b) when early market entry 
is preferred for new products or (c) when it is used to sup-
port the national pharmaceutical industry. This is due to the 
tendency pharmaceutical manufacturers have to set high 
entry prices for new products in countries without strict 
regulations, making these prices indicative for other coun-
tries that use ERP as a way to regulate prices in their own 
markets [4]. If manufacturers accept a lower than they expect 
price in one country, it may not only undermine their future 
price in another country where the product has not yet been 
launched, but may also undermine revenue based on its cur-
rent higher price in the first country, due to spillovers and 
parallel exports [8]. A study [20] has documented the poten-
tial spillover impact of ERP across countries in the case of a 
price reduction due to ERP in a single country implementing 
ERP: assuming all study countries re-reference Greek/Swiss 
prices, a 10% drop in the Greek price was accompanied by 
estimated losses for industry of €299 million in Greece, 
€799 million in other European countries, and €2,154 mil-
lion worldwide, whereas a 10% price reduction in the Swiss 
price reduced industry revenue by €430 million in Switzer-
land and €495.2 million worldwide [20]. In a simulation 
exercise, when assessing the impact of a price reduction in 
Germany on the drug prices in a number of European coun-
tries using ERP (i.e. Austria, Greece, Ireland, Italy, Luxem-
bourg, The Netherlands and Portugal), it was found that a €1 
reduction in German prices translated into a price reduction 
of €0.09 in Austria, which uses Germany as a reference. An 
additional, indirect, reduction of €0.15–€0.19 would also 
be seen as a result, as Austria benchmarks several coun-
tries that use Germany in their reference basket. Therefore, 
price changes in Germany may have a cross-border impact 
in countries referencing Germany [4]. In Italy, the effects of 
price decreases across Europe were found to cause price ero-
sion in the entire pharmaceutical market over time [24–28]. 
It has been argued that the impact of other countries’ prices 
on the launch prices in a given country varies according to 
the type of pharmaceutical product. Evidence from Europe 
shows that launch prices of innovative and highly effica-
cious products are positively correlated with the lowest 
price received in high-price countries but the launch prices 
of ‘me too’ products are positively correlated with the lowest 
price received in high-price EU countries only [4, 8]. The 
practice of agreeing to confidential rebates can also have an 
external effect as countries using ERP can only reference 
non-transactional prices, resulting in “list-price inflation”. 
Clawbacks have a similar effect as the price is effectively 
changed post-transaction, after the list price has affected the 
global price via ERP [29]. In conclusion, the fact that confi-
dential list price discounts exist can influence the ability of 
ERP to stabilise prices across countries and can further limit 
its credibility as a pricing policy, in that it can only serve as 
a starting point in price negotiations.
Price convergence
This endpoint examines the potential consequences of ERP 
in terms of upward or downward price convergence or price 
divergence across those countries using ERP. One potentially 
predictable impact of ERP implementation across countries 
is some level of international price convergence or harmoni-
sation, although evidence from the literature is contradictory 
[8]. Three issues were identified in this context: first, the 
overall ability of ERP to harmonise prices across countries; 
second, whether this ability is observed over the long-term; 
and finally, the factors affecting any price convergence trend, 
which can be upwards, downwards or towards the mean. 
This final point is further divided into two issues based on 
the influence of, both, the ERP methodology and other exog-
enous factors on price convergence observed.
Overall, some price convergence has been detected in 
certain European countries, Canada and other OECD coun-
tries, due to extensive use of ERP [8, 22, 30]. Evidence from 
2014, which compared average and minimum prices to mean 
prices of innovative pharmaceuticals and non-pharmaceu-
tical services in six Middle East countries, showed that 
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ERP systems reduced the pharmaceutical price differentials 
between countries with different economic status, resulting 
in a narrower price corridor for innovative pharmaceuticals. 
The average price corridor for innovative pharmaceuticals 
ranged between − 39.8% and + 35.9% in the study coun-
tries; in contrast, non-pharmaceutical outpatient and hospital 
services, which were not subjected to ERP, resulted in a 
price corridor ranging between − 81.7 and + 96.3% [14]. 
In a 2005 Eurostat study, which examined the prices of ten 
on-patent medicines in 15 Western European countries from 
2007 to 2012 to assess levels of convergence of ex-factory 
prices, a price divergence between 2008 and 2012 was 
shown and is believed to have been driven by two countries, 
Germany, where pharmaceuticals were 27% more expensive 
than the average, and Greece, where pharmaceuticals were 
32% cheaper than the average. All other European countries 
in the study had prices that were close to the average [20].
In the long run, although there appears to be some con-
vergence, the contribution of ERP was shown to be small at 
best [2, 9]. This was confirmed by simulation results, where 
ERP was assumed to be the sole price intervention mecha-
nism, demonstrating an average drug price decrease of about 
15% over 10 years. The price differentials between countries 
remained substantial—around 30%—over these 10 years, 
suggesting a limited impact of ERP in price convergence.
Larger baskets and an increase in basket size over time are 
associated with some price convergence in European phar-
maceutical prices [3–5, 31–35]. The degree of price conver-
gence is also determined by the design of the ERP system, 
and, in particular, the ERP formula and the frequency of 
price revisions. In this context, a simulation exercise has 
led to the argument that ERP can lead to a downward price 
convergence in Europe when the lowest price in the country 
basket, rather than the average price, is used to calculate the 
reference price [9].
With regards to exogenous factors affecting price con-
vergence when ERP is applied, it has been found that cur-
rency fluctuations in Europe and parallel trade can contrib-
ute to price convergence [9], although there may be other 
confounders contributing to this, such as different pricing 
policies implemented across countries [9]. However, the 
evidence synthesised in this section should be seen as being 
independent of other pricing schemes as these regulations 
could either be applied across the board or could have been 
used in a selective manner, i.e. for specific pharmaceuti-
cal products only.
Launch delays
This section examines the existence of delays in the launch 
of new pharmaceuticals in other countries solely as a result 
of ERP. Launch delays are usually calculated as the differ-
ence in months between marketing authorisation and the 
country-specific launch date [7, 11]. Four issues were identi-
fied under this endpoint: first, the impact of ERP on pharma-
ceutical launch in general; second, whether ERP promotes 
launch sequencing; third, the broader circumstances under 
which launch delays and launch sequencing can occur; and, 
fourth, whether ERP affects product launch in the long run.
Throughout the identified literature, the relationship 
between ERP and launch delays is ambiguous as the extent 
of these delays varies across countries [3, 7, 11, 12, 21, 36]. 
Evidence shows that from 1994 to 1999, the three coun-
tries with the greatest number of launches were Sweden, 
Denmark and Germany, whereas the four countries with the 
fewest number of launches were Portugal, Italy, Greece, and 
Spain; the average launch delay, as defined above, ranged 
from 8.1 months in Germany to 17.4 months in Belgium 
[11, 21]. The average delay for in-patent oncology pharma-
ceuticals was calculated for 2001–2013 using IMS data and 
a post-only design. Portugal had the largest launch delays 
and had to wait an average of 46 months after the launch of 
new oncology pharmaceuticals in other European markets. 
Switzerland and the Netherlands, on the other hand, waited 
just 5 months for the same products. For diabetes pharma-
ceuticals, Croatia had the longest delay at 37 months, while 
Switzerland had one of the shortest delays at just 1 month. 
Five other European countries with higher GDP, waited only 
about 2 months [12].
“Launch sequence strategy” is used by manufacturers 
as a strategy to delay or avoid launching new pharmaceu-
ticals in countries with lower prices and/or low sales vol-
ume, particularly if these are small markets referenced by 
countries with larger markets [4, 5, 7–10, 20]. For instance, 
manufacturers may strategically delay the launch of a new 
product in a lower-price country if that country’s prices 
will lower prices in higher-price countries as a result of the 
ERP spillovers [3, 11, 12, 36–40]. In Slovakia, the Ministry 
of Health allowed a 10% higher launch price than the aver-
age price of the three lowest-priced reference countries so 
pharmaceutical companies would not delay launching. By 
launching their new pharmaceuticals in Slovakia, manufac-
turers were able to price their drugs above the lowest price 
elsewhere in Europe, allowing room to launch their products 
before the price was established in other low-price countries 
as well as keep the Slovak price higher than elsewhere in 
Europe [41].
Evidence on the impact of ERP on launch sequencing 
strategies is available from a post hoc assessment of second-
ary data arising from relevant literature on time-to-market 
access and the price levels of innovative pharmaceuticals 
in 33 EU countries. This assessment showed that in Bel-
gium, companies systematically delayed dossier submis-
sion in order to avoid the Belgian price, which is typically 
not among the highest within the EU [20]. Furthermore, in 
market research reports for Taiwan [42, 43] and Turkey [44], 
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regression-based forecasts expressed concerns that manufac-
turers might be reluctant to launch new medicines in these 
countries as they would be subjected to low prices imme-
diately. Overall, it appears that countries having lower than 
expected prices tend to have fewer products launched and 
face longer launch delays [7, 11, 13, 45–49]. This observa-
tion is not without confounders and may also be related to 
longer bureaucratic processes required to reach price agree-
ments with governments.
Pharmaceutical firms may also delay launching their 
products in a country due to the ERP policy itself, or in situ-
ations where they assume that the resulting price will be pro-
hibitively low in a particular market. Evidence suggests that 
manufacturers are less willing to launch in countries where 
ERP is implemented due to the impact ERP has on price 
levels [4, 8, 10, 12, 29, 50] and are more likely to launch 
innovative pharmaceuticals in countries with more lax regu-
lations, where there is freedom to set entry prices because of 
the concomitant effects on third countries’ reference baskets  
[4, 5, 7, 8, 10–12, 30, 45–49, 51]. During the mid-to-late 
1990s, launch-price regulating countries (Greece, Belgium 
and France), had the longest average delay between drug 
approval and marketing, compared with non-price regu-
lating countries (Germany, the USA and the UK), which 
had the shortest average delay [11]. A European Commis-
sion study showed that when manufacturers were asked 
about their preferences for launching a new product they 
listed countries with the least interventionist pricing sys-
tem (i.e. UK, Germany, Sweden) as preferred for product 
launch purposes, in contrast to countries with smaller mar-
kets (e.g. Cyprus or Malta), or with lower disposable income 
(e.g. Poland, Bulgaria, Lithuania, Latvia, Estonia, Hungary 
and Romania), which are also associated with price regula-
tion through ERP [7]. Overall, lower income Eastern and 
Southern European countries, which implement stricter 
price regulations, tend to face longer delays than their 
Western and Northern European counterparts with higher 
GDP per capita [3, 12, 36]. Evidence has shown that market 
size matters and larger markets experience shorter launch 
delays compared to smaller ones as manufacturers weigh 
the opportunity costs of launch delays with the benefit of 
a prompt launch in potentially high-volume markets. This 
dominates any incentive regulators have to delay the launch 
of high-volume products that could have a disproportionate 
budget impact [11].
With regards to the factors affecting launch delays when 
ERP is implemented, EU Member States seem to be more 
exposed to spillover effects than non-EU countries due to the 
existence of parallel trade among the former, the majority of 
which formally, or informally, implement ERP to determine 
pharmaceutical prices. The interdependence of European 
countries gives an additional incentive to manufacturers to 
launch new pharmaceuticals in high-price countries first and 
to delay launch, or even prevent launch entirely, in low-price 
countries [52]. Parallel trade effectively arbitrages price dif-
ferences across countries and thus, has a similar effect to 
ERP in terms of compressing price differences and inducing 
strategic launch behaviour by firms [4, 7]. Therefore, even 
though there is evidence of strategic launching due to ERP, 
its impact on timely access in low price countries is unclear 
as other factors may contribute to this, including the likeli-
hood of parallel trade [20].
Evidence assessment
As impact assessment studies in pharmaceutical policy 
have been found to be weak, often casting doubt on many 
of the conclusions drawn, we critically assessed the quality 
of evidence used in this systematic review by appraising 
the methodological design of the identified studies. Ran-
domised control trials (RCTs) and studies with strong quasi-
experimental designs (e.g. time-series with a comparison 
group), are considered to be well-controlled compared to 
before-after or post-only studies, which are considered to 
be weaker designs, often producing unreliable results [19]. 
None of the studies included in this paper was identified 
with an experimental design or a strong quasi-experimen-
tal design and most had weak quasi-experimental designs. 
Twelve studies presented evidence on the impact of ERP on 
price stability, including two peer-reviewed studies and ten 
studies from grey literature. Of these, two were descriptive, 
presenting different pharmaceutical pricing regulations as 
well as the modalities of ERP in European countries and its 
potential impact [23, 29] and one study developed simula-
tion models to test several hypotheses about the effects of 
ERP [9]. Empirical evidence was collected by one study 
using a regression model [4] and by eight descriptive studies 
examining the promotion of price stability as a result of ERP 
systems across European and OECD countries, referencing 
other studies employing regression analysis or a post-only 
design [7, 8, 20, 24–28]. Three out of the 12 studies provided 
evidence on the potential long-term effect of ERP on price 
stability [7–9]. Fifteen studies were identified presenting evi-
dence on the impact of ERP on price convergence. Of these, 
8 were peer-reviewed and 7 were derived from grey litera-
ture. Five of the 15 studies were descriptive, discussing the 
current healthcare situation of the study countries [31–35], 
2 used a simulation exercise to assess the price dynam-
ics through ERP-based systems [2, 9] and one developed 
a theoretical model to study whether pharmaceutical firms 
are incentivised to launch their products in countries imple-
menting ERP [3]. Empirical evidence was extracted from 
7 studies, of which 2 used data through a post-only design, 
collected either from competent authorities or the Eurostat 
database [8, 20] and 5 studies analysed whether ERP leads 
to price convergence using either regression [4, 5, 14, 30] 
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or difference-in-differences analysis [22]. Four out of the 15 
studies provided long-term evidence by studying the effect 
of ERP on price convergence over a period of more than 5 
years [8, 9, 20, 22]. Four studies provided a general descrip-
tion of the type of cross-country spillover effects caused 
by ERP systems and the process by which these might be 
triggered. Two of these were peer-reviewed. Three studies 
provided descriptive evidence drawn from Europe [8, 12, 
20], whereas one descriptive study provided quantitative evi-
dence with a post-only design using data from IMS and from 
competent authorities, when studying potential spillover 
effects of ERP [12]. The final study was empirical using a 
regression model to examine the potential impact of ERP on 
pharmaceutical prices [4]. Thirty-one studies looking at the 
impact of ERP on the launch of new pharmaceuticals were 
identified in the literature. Of these, 14 were peer-reviewed 
and 17 were extracted from grey literature. Fourteen studies 
were descriptive [5, 38, 39–51], eight were both descrip-
tive and empirical in nature describing ERP systems and 
their modalities using post-only data from readily available 
sources and from IMS [7, 8, 10, 12, 20, 29, 39, 52] and, 
additionally, two descriptive studies referenced an empirical 
study with a regression model when studying launch delays 
in other countries [13, 21]. Three studies built a theoreti-
cal model to test how firms respond to the launch of their 
pharmaceuticals in countries implementing ERP [3, 36, 37] 
and one study performed a simulation exercise [9]. Finally, 
three studies were purely empirical using a regression model 
to test whether price regulation affects the launch of a phar-
maceutical in specific countries [4, 11, 30]. From the 31 
studies included in this endpoint, 6 provided long-term evi-
dence on the impact of ERP on launch delays [7, 9–12, 21]. 
Table 3 presents the overall direction of evidence and quality 
of existing evidence found in the available literature on the 
impact of ERP across countries.
Primary data collection
Of the 21 countries that formed part of the primary data 
collection process, 17 countries (Belgium, Brazil, Bulgaria, 
Egypt, Spain, Estonia, Greece, Hungary, Italy, Latvia, 
Poland, Qatar, Romania, Russia, Slovenia, South Africa and 
Jordan) and a total of 19 stakeholders (2 each from Hun-
gary and Brazil) responded to the survey questions providing 
feedback on whether the international implications of ERP 
are taken into account during the design phase of ERP. In 
Egypt, Estonia, Hungary, Latvia, Qatar, Russia, Slovenia 
and South Africa, the international implications of ERP are 
not considered during its design [53]. Similarly, in Roma-
nia, the likely effect from parallel trade, arising from price 
differences between Romania and other countries, is not 
considered in the ERP design, even though there is exten-
sive evidence of this phenomenon in the country [53]. There 
was limited information from Spain, in terms of the basis 
on which the design of ERP was informed; therefore, we 
are unable to comment on whether or not the international 
implications of ERP are considered [53] by decision-makers 
in these cases. In Greece, Jordan and Slovakia the interna-
tional effects of ERP are considered, mainly because all are 
used as reference countries and decision-makers are aware 
of the international spillover effects of ERP, particularly 
those relating to parallel trade [53]. Specifically, in Greece 
and Slovakia parallel trade often results in drug shortages, 
which is why in the former case, the government has on 
several occasion issued temporary export bans to discourage 
products from leaving the country [53]. In Belgium, parallel 
trade is consistently highlighted as a problem by the industry 
and is stated as a reason why they cannot allow lower list 
prices [53]. In Bulgaria, parallel trade is considered in the 
design of ERP and the focus is mostly on parallel exports, 
due to the increased likelihood of shortages [53]. In Poland, 
the ERP system is no longer used explicitly to inform prices. 
However, spillover effects and parallel trade are considered 
when manufacturers maintain a higher official price, which 
is publically available [53]. In Brazil, the international impli-
cations considered during the ERP design are the growth 
of parallel trade after the initiation of ERP and spillover 
effects caused by positive restrictive formularies and guide-
lines [53].
Discussion and policy implications
The evidence identified on the impact of ERP across coun-
tries showed that ERP may lead to price convergence, price 
instability and launch delays and has significant spillover 
effects. Table 2 summarises the available evidence from 
across the body of identified literature.
With regards to the general cross-country spillover effects 
and the link to ERP, spillover effects have unintended con-
sequences in countries where ERP is the dominant method 
in price setting. The impact of spillover effects due to the 
nature of ERP has been documented, showing that ERP una-
voidably follows a deterministic pathway in which prices can 
decline across countries if one country applies price cuts or 
if launch prices in some settings are lower than in others. 
Primary data collection suggested that only 47% of countries 
consider the international implications of ERP when design-
ing their ERP system. By considering these effects during 
the design process, many countries could have prevented at 
least some of the undesirable consequences of this pricing 
policy.
Evidence on whether ERP contributes to price stabil-
ity is complex to interpret, as it may be linked to other 
parameters operating in tandem. A limited number of 
studies concluded that ERP most likely leads to price 
instability across countries, as price fluctuations in one 
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country trigger price fluctuations elsewhere, leading to 
higher prices and lower availability of medicines. One 
could argue that as ERP is a tool used to regulate pharma-
ceutical prices across countries, its potential to stabilise 
pharmaceutical prices across countries should be high. 
However, evidence shows that prices actually fluctuate 
due to numerous factors, including market characteristics, 
the variable designs in ERP systems, currency fluctua-
tions, manufacturers’ incentives, type of pharmaceutical 
products (innovative or me-too) and specific country-based 
regulations, which contribute to price instability across 
countries. Price convergence is also likely to occur when 
ERP is implemented across countries at least in the short-
term. The evidence presented in this study showed that 
Table 3  Evidence synthesis on the international impact of ERP Source: Synthesis by the authors
a The “+” sign indicates that ERP contributes to achieving the stated goal(s) whereas the “−” sign indicates that it does not contribute to achiev-
ing the stated goal(s). The sign “+/−”is used where the impact of ERP on the relevant endpoint/issue is ambiguous. This is generally observed 
when the impact of ERP depends on other factors, such as the modalities of ERP methodology or other exogenous factors. A simple-vote count-
ing methodology was used by counting the number of the identified studies providing positive evidence and the number of those providing nega-
tive evidence
b The overall quality of the identified empirical evidence has been classified as high, moderate, low, very low and not available. Only studies 
examining each endpoint/issue empirically were considered. Quasi-experimental designs had a ‘high’ classification, post-only designs were clas-
sified as ‘very low’, whereas studies performing a regression analysis had a ‘moderate’ classification. Under each endpoint/issue, when different 
types of empirical studies were considered, the quality of evidence was then assessed according to the majority
c Represents an overall estimation of the extent of evidence on whether adequate evidence was identified in terms of number of studies regardless 
of their quality. A grading system is used here, denoted by the number of studies included under each endpoint and the identified key issues; if 
the evidence presented under each endpoint/issue was derived from 22 or more studies, the extent of this evidence was classified as high; from 
15 to 21 as moderate; from eight to 14 as low; from one to seven studies as very low; and zero studies as not available
d Refers to the timeline covered by the relevant evidence and whether this is predominantly short- (“S”) or long-term (“L”). If both, then “S/L” is 
used
Study endpoints Issues identified within 
endpoints
Impact of ERP
Positive (+) Negative 
(−) or Ambiguous 
(+/−)a
Quality of empiri-
cal evidence on the 
impact of ERP (where 
applicable)b
Overall extent of 
evidence on the impact 
of  ERPc
Duration evidence 
applies to: short-term 
(S) or long-term (L)d
Spillover effects Impact of spillover 
effects
+ Very low Very low S
Price stability ERP has the ability to 
promote price stabil-
ity across countries
– Very low Low L
Price stability depends 
on ERP design
+/− Very low Very low
Price stability depends 
on market character-
istics
+/− Very low Low
Price convergence ERP leads to price 
convergence across 
countries
+/− Low Moderate S
Type of price conver-
gence depends on 
ERP design
+/− Very low Low
Price convergence 
depends on exog-
enous factors other 
than ERP
+/− Very low Very low
Launch delays Impact of ERP on phar-
maceutical product 
launch
+/− Low High S/L
Impact of ERP on 
launch sequencing
+/− Very low High
Launch delays depend 
on factors other than 
ERP
+/− Low Moderate
Overall +/− Very low Low Mainly S
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ERP systems are expected to reduce pricing differentials, 
but there are examples where price divergence is also 
observed.
Evidence on launch delays varies considerably across 
countries. Our findings suggest that launch delays depend 
on various determinants such as country disposable 
income, market size, the overall regulatory environment 
and manufacturer pricing and entry strategies. One could 
argue that other regulatory interventions used in price 
setting and/or reimbursement can lead to launch delays. 
Health technology assessment (HTA) is one such interven-
tion and, depending on the model pursued (rapid review 
vs. full deliberative model), it can lead to moderate to 
significant delays in access [54–56]. Despite these, the 
outcome of HTA is in the vast majority of cases positive 
or positive with restrictions [57, 58]; ERP by contrast, 
can result in a long delay and, in some cases, permanent 
non-entry, if price levels in the target country are expected 
to be low enough as to pose a threat to manufacturers’ 
global pricing and market entry strategies.
As shown extensively throughout the literature, launch 
sequencing and delays have international consequences by 
limiting the access to and availability of pharmaceuticals in 
smaller countries, in those with low price levels and those 
with stricter price regulations or those who must wait for 
other countries to make a decision on both reimbursement 
and price. Therefore, although ERP aims to deliver better 
control of prices and faster price erosion, it might also lead 
to unwanted effects, such as triggering increases in list prices 
by manufacturers in order to avoid both parallel trade and 
any potential impact on revenues [20].
Findings from both this study and another, looking at 
the impact of ERP within countries [15], highlight a bi-
directional relationship between the impact of ERP within 
and across countries. Potential price convergence caused by 
ERP reinforces narrow price ranges across countries, which 
can be unfavourable for low-income countries facing price 
increases generally towards the basket average. As such, it 
may hinder availability and affordability of pharmaceuticals 
within a country. At the same time, launch delays caused 
by lower price levels resulting from ERP in third countries 
would result in non-availability of pharmaceuticals.
Both the impact of ERP at national and international lev-
els depend largely on the design of the ERP system and 
other exogenous factors. It has been explicitly stated in the 
literature that country-specific characteristics, such as mar-
ket size, health system regulations, other pricing mecha-
nisms employed, and the nature and design of the ERP sys-
tem play a pivotal role on the impact ERP has both within 
and across countries. Income levels, proxied by GDP per 
capita, have also been shown to have an indirect relationship 
with ERP impact, by influencing the extent of launch delays. 
Specifically, GDP per capita levels are in principle inversely 
related to launch delays.
ERP has been criticised for “path dependence”, suggest-
ing that the features of the ERP system shape the overall 
impact it has. Consequently, by calibrating certain features 
of ERP its overall function can be optimised. For instance, 
the formula used to calculate prices within the ERP system 
needs to be set more cautiously: using an average-based 
formula could reduce launch delays, promote availability 
and, ultimately, contribute to price stability across countries. 
Countries in the basket (and their corresponding currencies), 
the size of the basket, the timing of price revisions and the 
exchange rate used for this purpose, should be selected care-
fully so that unwanted effects, such as exchange rate volatil-
ity, which can cause price instability across countries, can 
be minimised. Consequently, and based on the evidence 
from the literature, by modifying certain elements of the 
overall ERP system design to revise prices at less frequent 
intervals (e.g. annually or every 5 years, rather than every 
quarter or even twice annually), decreasing the basket size 
and avoiding referencing countries with intense price regu-
lations, spillover effects experienced due to ERP could be 
minimised. These suggestions are broadly in line with a set 
of 14 principles [59] recommended for the development of 
an ‘ideal’ ERP system which are discussed in more detail 
in another paper in this series, which outlines the variation 
seen in the implementation of ERP systems in a number of 
countries [16].
Despite the relative wealth of evidence found on the 
impact of ERP across a country’s borders, we conclude that 
any such impact remains ambiguous due to the limited num-
ber of empirical studies and their relatively weak research 
design. Specifically, we can conclude that the strength and 
the quality of evidence on the impact of ERP on spillover 
effects is very low. The identified empirical evidence regard-
ing the ability of ERP to result in price stability and price 
convergence across countries uses, in most part, weak meth-
odological designs, resulting in both low quality of evidence 
and a lack of quantifiable evidence. The strength of evidence 
on the impact of ERP on launch delays and launch sequenc-
ing is relatively high compared to other endpoints. However, 
the quality of evidence on this endpoint is still relatively 
weak, arising from a post-only analysis and three regres-
sion models. Few examples exist in the literature showing 
long-term measureable impact. Therefore, any interpretation 
of results stemming from the literature on “launch delays” 
should be interpreted with caution. A better understanding is 
needed of the reasons behind pharmaceutical launch delays, 
and whether these are experienced in the presence of ERP 
over time [13].
Overall, the evidence presented in this paper is clas-
sified as poor in terms of quality, as it comprised only a 
limited volume of empirical evidence with acceptable (e.g. 
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quasi-experimental) designs that would lead to robust con-
clusions. Some of the evidence reviewed was based on 
qualitative analysis of survey data or regression analyses of 
observational data, where bias and/or potential confound-
ers could not be controlled. In addition, as the majority of 
the evidence considered is short-term in nature, no major 
conclusions can be drawn about the longer-term implica-
tions of ERP. A key finding is that the majority of studies 
(67%) looking into the international implications of ERP 
comes from grey literature, which predominately comes 
from official reports of the European Union, the WHO and 
the OECD. Although we cannot justify fully why evidence 
on ERP derives  mainly from grey literature, and, specifi-
cally, international organisations, we surmise that the latter 
have a keen interest in the impact of pricing policies, their 
effectiveness and wider implications.
Robust research using empirical evidence with strong 
methodological design and a longer time horizon is urgently 
needed to understand and, eventually, interpret the drivers 
influencing the impact of ERP across countries. Neverthe-
less, this is becoming cumbersome, as ERP is increasingly 
used as a starting point of negotiations or in combination 
with other pricing policies, which suggests that there is a 
whole host of parameters and confounders that need to be 
accounted for in order to evaluate its performance. One of 
them is the increased use of confidential discounting, which 
renders ERP largely ineffective as a price control tool, as 
list prices for most new products are fictitious as they do 
not incorporate discounts or other arrangements negotiated 
between competent authorities and manufacturers in refer-
ence countries.
Limitations
A number of limitations were encountered, mainly due to 
limitations experienced when performing the systematic lit-
erature review. First, the literature was scanned using online 
databases, where the results were limited to English. As a 
result, relevant studies published in a language other than 
English were excluded. Second, as pharmaceutical pricing 
policies are constantly updated and undergoing change, the 
evidence presented in this systematic literature review may 
not reflect the policy landscape in the future. However, this 
study provides a benchmark at a specific point in time and 
could inform future comparisons. Third, a significant pro-
portion of the studies reviewed came from grey literature, 
were mostly descriptive in nature, had weak methodological 
designs and, consequently, were perceived as low quality. 
However, even weak designs, such as pre–post analysis, can 
provide meaningful input in circumstances where evidence 
is altogether missing. Finally, while we performed an assess-
ment of the quality of evidence of the studies that met the 
inclusion criteria, we did not follow or use formal critical 
appraisal and assessment tools for systematic reviews to 
assess their methodological quality, but instead, focused on 
the type of design (experimental, non- or quasi-experimen-
tal) that was implemented. This does not necessarily reduce 
the validity of the results obtained and was chosen in rec-
ognition of the fact that none of the policy studies identified 
had an experimental design.
Conclusion
ERP appears to be associated with international implica-
tions, including spillover effects, price instability, price 
convergence and launch delays; these have been widely 
observed across countries. However, these effects cannot be 
solely attributed to or caused by ERP per se and there may be 
other factors at play; market size and income levels (in terms 
of GDP per capita) of a country, exchange rate fluctuations 
as well as other supply-side regulations can either trigger 
one or more of these effects or, indeed, reduce their impact. 
Nevertheless, the nature of ERP facilitates these unintended 
consequences and directly links them to it. Despite these 
cross-country implications being well known to decision-
makers, they are not necessarily considered when the design 
of ERP systems takes place.
Given that the evidence we found in the currently avail-
able literature was mostly weak in terms of quality and 
derived mainly from grey literature, the above observations 
should be interpreted with caution. Importantly, there seems 
to be a dual unmet need: the first, relates to what constitutes 
an optimal ERP system design, so that its impact across 
countries would be at least neutral; and, the second, relates 
to the robust quantification of its impact at international 
level, including practices countries have used to address 
spillover effects.
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